BioCardia receives positive FDA feedback for CardiAMP PMA pathway
BioCardia (NASDAQ:BCDA) announced that minutes from a recent pre-submission (Q-Sub) meeting with the U.S. Food and Drug Administration (FDA) have provided a clearer regulatory roadmap for its CardiAMP Cell Therapy System.
According to the company, the feedback indicates that the ongoing CardiAMP Heart Failure II (HF II) pivotal trial may be sufficient to support a Premarket Approval (PMA) application for the treatment of ischemic heart failure with reduced ejection fraction (HFrEF).
The CardiAMP system utilizes a patient's own bone marrow cells, processed at the point of care, to treat damaged heart tissue.
While the FDA has historically expressed a preference for two robust, independent clinical trials for broad, high-impact indications like HFrEF, the current regulatory signals offer BioCardia a potential path to market authorization based on the results of the ongoing Phase 3 trial.
This progress follows significant regulatory and reimbursement milestones for the company.
The FDA has already deemed the CardiAMP system safe enough to enable Centers for Medicare and Medicaid Services (CMS) reimbursement for participants enrolled in the CardiAMP HF clinical trials, a status that underscores the agency’s recognition of the program's safety profile.
The CardiAMP HF II trial remains the core of BioCardia's clinical strategy as it seeks to demonstrate clinical efficacy in a patient population with limited therapeutic alternatives.
